Slingshot members are tracking this event:

AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
- Trial will study efficacy and safety of venetoclax in combination with bortezomib and dexamethasone in patients who are considered sensitive or naïve to proteasome inhibitors who have received 1 to 3 prior lines of therapy for multiple myeloma(1) 
- Multiple myeloma is a cancer formed by malignant plasma cells and is the second most common type of blood cancer(2)
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 28, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Venetoclax, Refractory Multiple Myeloma